Home FDA labels 864765dd-5213-c5bf-e053-2991aa0a70bd FDA label 864765dd-5213-c5bf-e053-2991aa0a70bd openFDA label record# This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)
SPL set ID 747a5b5b-fe25-4c78-a9cc-662ebffc3183
SPL ID 864765dd-5213-c5bf-e053-2991aa0a70bd
Version 4
Effective date 2019-04-11
Source export date 2026-09-28
Source partition 11
Source file https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key raw/openfda/drug-label/2026-09-28/aa96b5a2be6b394393acd0090f6948bdf99e0e8e00666f81608929c8fa83db77/drug-label-0011-of-0014.json.zip
Source manifest SHA-256 cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run 20260929T050834Z
Imported at 2026-09-29 06:21:09 Harmonized identifier links# Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
Harmonized identifiers page 1 of 1 · 2 matching rows.
Warnings cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings and cautions 5 WARNINGS AND PRECAUTIONS Acute renal failure Cases of acute renal failure have been reported in patients with underlying renal disease who have received inappropriately high doses of famciclovir tablets for their level of renal function. Dosage reduction is recommended when administering famciclovir tablets to patients with renal impairment [see Dosage and Administration ( 2.3 ), Use in Specific Populations ( 8.6 )]. Acute renal failure: May occur in patients with underlying renal disease who receive higher than recommended doses of famciclovir for their level of renal function. Reduce dosage in patients with renal impairment. ( 2.3 , 8.6 )
Adverse reactions cross-check# openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions sections page 1 of 1 · 3 matching rows.
adverse reactions 6 ADVERSE REACTIONS Acute renal failure is discussed in greater detail in other sections of the label [see Warnings and Precautions ( 5 )]. The most common adverse events reported in at least 1 indication by >10% of adult patients treated with famciclovir are headache and nausea. The most common adverse events reported in at least 1 indication by >10% of adult patients are headache and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Drug Information Service at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience in Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Immunocompetent patients The safety of famciclovir has been evaluated in active- and placebo-controlled clinical studies involving 816 famciclovir-treated patients with herpes zoster (famciclovir, 250 mg three times daily to 750 mg three times daily); 163 famciclovir-treated patients with recurrent genital herpes (famciclovir, 1,000 mg twice daily); 1,197 patients with recurrent genital herpes treated with famciclovir as suppressive therapy (125 mg once daily to 250 mg three times daily) of which 570 patients received famciclovir (open-labeled and/or double-blind) for at least 10 months; and 447 famciclovir-treated patients with herpes labialis (famciclovir, 1500 mg once daily or 750 mg twice daily). Table 2 lists selected adverse events. Table 2 Selected Adverse Events (all grades and without regard to causality) Reported by ≥2% of Patients in Placebo-Controlled Famciclovir Trials Patients may have entered into more than one clinical trial. Incidence Event s Herpes Zoster 7 days of treatment Recurrent Genital Herpes 1 day of treatment Genital Herpes-Suppression daily treatment Herpes Labialis Famciclovir n=(273) % Placebo (n=146) % Famciclovir n=(163) % Placebo (n=166) % Famciclovir (n=458) % Placebo (n=63) % Famciclovir (n=447) % Placebo (n=254) % Nervous System Headache 22.7 17.8 13.5 5.4 39.3 42.9 8.5 6.7 Paresthesia 2.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 Migraine 0.7 0.7 0.6 0.6 3.1 0.0 0.2 0.0 Gastrointestinal Nausea 12.5 11.6 2.5 3.6 7.2 9.5 2.2 3.9 Diarrhea 7.7 4.8 4.9 1.2 9.0 9.5 1.6 0.8 Vomiting 4.8 3.4 1.2 0.6 3.1 1.6 0.7 0.0 Flatulence 1.5 0.7 0.6 0.0 4.8 1.6 0.2 0.0 Abdominal Pain 1.1 3.4 0.0 1.2 7.9 7.9 0.2 0.4 Body as a Whole Fatigue 4.4 3.4 0.6 0.0 4.8 3.2 1.6 0.4 Skin and Appendages Pruritus 3.7 2.7 0.0 0.6 2.2 0.0 0.0 0.0 Rash 0.4 0.7 0.0 0.0 3.3 1.6 0.0 0.0 Reproductive (Female) Dysmenorrhea 0.0 0.7 1.8 0.6 7.6 6.3 0.4 0.0 Table 3 lists selected laboratory abnormalities in genital herpes suppression trials. Table 3 Selected Laboratory Abnormalities in Genital Herpes Suppression Studies Percentage of patients with laboratory abnormalities that were increased or decreased from baseline and were outside of specified ranges. Parameter Famciclovir (n=660) n values represent the minimum number of patients assessed for each laboratory parameter. % Placebo (n=210) % Anemia (<0.8 x NRL) 0.1 0.0 Leukopenia (<0.75 x NRL) 1.3 0.9 Neutropenia (<0.8 x NRL) 3.2 1.5 AST (SGOT) (>2 x NRH) 2.3 1.2 ALT (SGPT) (>2 x NRH) 3.2 1.5 Total Bilirubin (>1.5 x NRH) 1.9 1.2 Serum Creatinine (>1.5 x NRH) 0.2 0.3 Amylase (>1.5 x NRH) 1.5 1.9 Lipase (>1.5 x NRH) 4.9 4.7 NRH=Normal Range High. NRL=Normal Range Low. HIV-infected patients In HIV-infected patients, the most frequently reported adverse events for famciclovir (500 mg twice daily; n=150) and acyclovir (400 mg, 5x/day; n=143), respectively, were headache (17% vs. 15%), nausea (11% vs. 13%), diarrhea (7% vs. 11%), vomiting (5% vs. 4%), fatigue (4% vs. 2%), and abdominal pain (3% vs. 6%). 6.2 Postmarketing Experience The adverse events listed below have been reported during postapproval use of famciclovir tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood and lymphatic system disorders Thrombocytopenia Hepatobiliary disorders Abnormal liver function tests, cholestatic jaundice Immune system disorders Anaphylactic shock, anaphylactic reaction Nervous system disorders Dizziness, somnolence, seizure Psychiatric disorders Confusion (including delirium, disorientation, and confusional state occurring predominantly in the elderly), hallucinations Skin and subcutaneous tissue disorders Urticaria, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema (e.g., face, eyelid, periorbital, and pharyngeal edema), hypersensitivity vasculitis Cardiac disorders Palpitations
adverse reactions table <table width="100%"> <caption>Table 2 Selected Adverse Events (all grades and without regard to causality) Reported by ≥2% of Patients in Placebo-Controlled Famciclovir Trials <footnote ID="_Ref497119586">Patients may have entered into more than one clinical trial.</footnote> </caption> <colgroup> <col width="15%"/> <col width="12%"/> <col width="9%"/> <col width="12%"/> <col width="9%"/> <col width="12%"/> <col width="9%"/> <col width="12%"/> <col width="9%"/> </colgroup> <tbody> <tr> <td align="center" colspan="9" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Incidence</content> </paragraph> </td> </tr> <tr> <td rowspan="2" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Event</content>s </paragraph> </td> <td align="center" colspan="2" styleCode="Lrule Botrule " valign="middle"> <paragraph> <content styleCode="bold">Herpes Zoster</content> <footnote ID="_Ref497119592">7 days of treatment</footnote> </paragraph> </td> <td align="center" colspan="2" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Recurrent Genital Herpes</content> <footnote ID="_Ref497119597">1 day of treatment</footnote> </paragraph> </td> <td align="center" colspan="2" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Genital Herpes-Suppression</content> <footnote ID="_Ref497119602">daily treatment</footnote> </paragraph> </td> <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Herpes Labialis</content> <footnoteRef IDREF="_Ref497119597"/> </paragraph> </td> </tr> <tr> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Famciclovir</content> <content styleCode="bold">n=(273)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n=146)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Famciclovir</content> <content styleCode="bold">n=(163)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n=166)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Famciclovir</content> <content styleCode="bold">(n=458)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n=63)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Famciclovir</content> <content styleCode="bold">(n=447)</content> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n=254)</content> <content styleCode="bold">%</content> </paragraph> </td> </tr> <tr> <td colspan="9" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Nervous System</content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Headache</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>22.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>17.8</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>13.5</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>5.4</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>39.3</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>42.9</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>8.5</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>6.7</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Paresthesia</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>2.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.9</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Migraine</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.1</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.2</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td colspan="9" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Gastrointestinal</content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Nausea</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>12.5</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>11.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>2.5</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>7.2</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>9.5</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>2.2</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>3.9</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Diarrhea</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>7.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>4.8</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>4.9</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.2</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>9.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>9.5</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.6</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.8</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Vomiting</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>4.8</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.4</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.2</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.1</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Flatulence</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.5</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>4.8</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.2</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Abdominal Pain</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.1</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.4</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.2</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>7.9</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>7.9</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.2</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.4</paragraph> </td> </tr> <tr> <td colspan="9" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Body as a Whole</content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Fatigue</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>4.4</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.4</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>4.8</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.2</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.6</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.4</paragraph> </td> </tr> <tr> <td colspan="9" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Skin and Appendages</content> </paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Pruritus</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>2.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>2.2</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td styleCode="Lrule Botrule " valign="top"> <paragraph>Rash</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.4</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>3.3</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>1.6</paragraph> </td> <td align="center" styleCode="Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td colspan="9" styleCode="Rrule Lrule Botrule " valign="top"> <paragraph> <content styleCode="bold">Reproductive (Female)</content> </paragraph> </td> </tr> <tr> <td styleCode="Botrule Lrule " valign="top"> <paragraph>Dysmenorrhea</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>0.0</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>0.7</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>1.8</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>0.6</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>7.6</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>6.3</paragraph> </td> <td align="center" styleCode="Botrule Lrule " valign="top"> <paragraph>0.4</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule " valign="top"> <paragraph>0.0</paragraph> </td> </tr> </tbody> </table>
adverse reactions table <table width="100%"> <caption>Table 3 Selected Laboratory Abnormalities in Genital Herpes Suppression Studies <footnote ID="_Ref497119876">Percentage of patients with laboratory abnormalities that were increased or decreased from baseline and were outside of specified ranges.</footnote> </caption> <colgroup> <col width="35%"/> <col width="35%"/> <col width="31%"/> </colgroup> <tbody> <tr> <td styleCode="Toprule " valign="top"> <paragraph> <content styleCode="bold">Parameter</content> </paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph> <content styleCode="bold">Famciclovir</content> <content styleCode="bold">(n=660)</content> <footnote ID="_Ref497119882">n values represent the minimum number of patients assessed for each laboratory parameter.</footnote> <content styleCode="bold">%</content> </paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n=210)</content> <footnoteRef IDREF="_Ref497119882"/> <content styleCode="bold">%</content> </paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Anemia (<0.8 x NRL)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.1</paragraph> </td> <td align="center" valign="top"> <paragraph>0.0</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Leukopenia (<0.75 x NRL)</paragraph> </td> <td align="center" valign="top"> <paragraph>1.3</paragraph> </td> <td align="center" valign="top"> <paragraph>0.9</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Neutropenia (<0.8 x NRL)</paragraph> </td> <td align="center" valign="top"> <paragraph>3.2</paragraph> </td> <td align="center" valign="top"> <paragraph>1.5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>AST (SGOT) (>2 x NRH)</paragraph> </td> <td align="center" valign="top"> <paragraph>2.3</paragraph> </td> <td align="center" valign="top"> <paragraph>1.2</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>ALT (SGPT) (>2 x NRH)</paragraph> </td> <td align="center" valign="top"> <paragraph>3.2</paragraph> </td> <td align="center" valign="top"> <paragraph>1.5</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Total Bilirubin (>1.5 x NRH)</paragraph> </td> <td align="center" valign="top"> <paragraph>1.9</paragraph> </td> <td align="center" valign="top"> <paragraph>1.2</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Serum Creatinine (>1.5 x NRH)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.2</paragraph> </td> <td align="center" valign="top"> <paragraph>0.3</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph>Amylase (>1.5 x NRH)</paragraph> </td> <td align="center" valign="top"> <paragraph>1.5</paragraph> </td> <td align="center" valign="top"> <paragraph>1.9</paragraph> </td> </tr> <tr> <td styleCode="Botrule " valign="top"> <paragraph>Lipase (>1.5 x NRH)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>4.9</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>4.7</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.